GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » 3-Year EPS without NRI Growth Rate

Botanix Pharmaceuticals (ASX:BOT) 3-Year EPS without NRI Growth Rate : 23.70% (As of Dec. 2023)


View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Botanix Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was A$-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 23.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Botanix Pharmaceuticals was 84.10% per year. The lowest was -56.50% per year. And the median was 30.50% per year.


Competitive Comparison of Botanix Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Botanix Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Botanix Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Botanix Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Botanix Pharmaceuticals  (ASX:BOT) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Botanix Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Botanix Pharmaceuticals (ASX:BOT) Business Description

Traded in Other Exchanges
Address
661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007
Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines